Ganetespib: Phase II started

Synta disclosed in its 3Q12 earnings that it began the open-label Phase II ENCHANT trial to evaluate twice-weekly 150 mg/m 2 IV ganetespib for 3 consecutive weeks in a 4-week cycle in about 70 patient...